cropped-gtc_logo_grey_circle_2022

ASCO 23 Posters

ASCO 23 posters available

GTC presented abstracts at ASCO 2023

GTC’s posters from 2023 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach out with any questions.

2023-ASCO poster - 3043


Distinguishing between cancer-related mutations and clonal hematopoiesis using cell-free RNA (cfRNA) expression levels in a machine learning model

2023-ASCO poster - 7060


Defining the immune microenvironment
in myelodysplastic syndrome
and acute myeloid leukemia
using machine learning

2023-ASCO Machine Learning poster - 2634

Using machine learning to characterize lung cancer microenvironment and the development of a model to predict the presence of similar microenvironment in other cancers

Read more Articles and News from GTC

ASCO 25 posters
Innovation

ASCO 25 Posters

GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please

Read More »
Article

GTC featured in OC Business Journal

GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025  Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with

Read More »

YOU MAY ALSO ENJOY THESE ARTICLES:

ASCO 25 Posters

GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please reach out with any questions.

Read More »

Next‑generation sequencing (NGS) detects presence of chimeric antigen receptor (CAR) T‑cell construct in a diffuse large B‑cell lymphoma patient with no response to CAR T‑cell therapy: a case report

Aishwarya Sridhar1 · Dylon Patel1 · Alexandra Della Pia2 · Tatyana A. Feldman2,3 · Lori A. Leslie2,3 · Andre H. Goy1,2 · Maher Albitar4 · Andrew Ip2,3Received: 27 June 2024 / Accepted: 19 November 2024© The Author(s) 2024 OPEN AbstractBackground CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized

Read More »

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends